| Drug General Information |
| Drug ID |
D0O3KA
|
| Former ID |
DNCL002337
|
| Drug Name |
RG7602
|
| Indication |
Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86]
|
Discontinued in Phase 1 |
[1]
|
|---|
| Company |
Array BioPharma; Roche
|
| Target and Pathway |
| Target(s) |
Serine/threonine-protein kinase Chk1 |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
Cell cycle
|
|
p53 signaling pathway
|
|
HTLV-I infection
|
|
Viral carcinogenesis
|
|
Pathway Interaction Database
|
Fanconi anemia pathway
|
|
p73 transcription factor network
|
|
ATR signaling pathway
|
|
Circadian rhythm pathway
|
|
p53 pathway
|
|
Reactome
|
Activation of ATR in response to replication stress
|
|
Processing of DNA double-strand break ends
|
|
Presynaptic phase of homologous DNA pairing and strand exchange
|
|
G2/M DNA damage checkpoint
|
|
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
|
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
|
|
WikiPathways
|
DNA Damage Response
|
|
Signaling by SCF-KIT
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Cell Cycle
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034639) |
|---|
| REF 2 | National Cancer Institute Drug Dictionary (drug id 701310). |
|---|
